Corporate Profile
The cancer treatment paradigm has shifted dramatically, providing evidence that the immune system can be educated to recognize and eliminate the patient’s tumor cells. At Candel Therapeutics, we are developing viral immunotherapies that induce immunogenic cell death in cancer cells at the site of injection, unmasking tumor antigens and neo-antigens within an activated microenvironment. This process leads to a systemic, durable immune response against the tumor through in situ vaccination, with the potential to change disease outcomes across a variety of indications. Candel’s product candidates are designed to improve survival while maintaining quality of life in patients with early- to late-stage disease.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Jun 05, 2023
May 19, 2023
May 11, 2023
Events
Jun 7, 2023 at 4:00 PM EDT
Dec 6, 2022 at 11:00 AM EST
SEC Filings
Filing date | Description | Form |
---|---|---|
A statement of beneficial ownership of common stock by certain persons |
SC 13G | |
A statement of beneficial ownership of common stock by certain persons |
SC 13G | |
Additional proxy soliciting materials - definitive |
DEFA14A |